PETITION FOR EXTENSION OF TIME

Applicants hereby request a one-month extension of time extending the time for response from January 7, 1997 up to and including February 7, 1997. The Assistant Commissioner is hereby authorized to charge the required $110.00 fee to Deposit Account No. 23-1703. Any additional fees due in connection with this Petition should likewise be charged.

Please amend the application as follows:

In the Claims:

~~8~~ 17. (twice amended) [A] The method [for the treatment of asthma and other inflammatory respiratory disorders, which comprises administering by inhalation to a host in need of such treatment effective amounts of a physiologically acceptable salt of formoterol or a solvate thereof, and budesonide] according to claim ~~1~~ 17, wherein the effective amount of the physiologically acceptable salt of formoterol or solvate thereof is 6-100 μg per day, and the effective amount of budesonide is 50-4800 μg per day.

Please add the following new claims:

~~20~~ 29. The method according to any one of claims ~~1~~ 17, ~~17~~ 18 and ~~18~~ 19, wherein the physiologically acceptable salt of

formoterol or the solvate thereof is administered in admixture with the budesonide.

9 ~~30.~~ A medicament containing as active ingredients effective amounts of a physiologically acceptable salt of formoterol or a solvate thereof, and budesonide wherein the molar ratio of the formoterol component to the budesonide component is in the range from 1:1 to 1:60.

12 ~~31.~~ A pharmaceutical composition which comprises effective amounts of a physiologically acceptable salt of formoterol or a solvate thereof, and budesonide wherein the molar ratio of the formoterol component to the budesonide component is in the range from 1:1 to 1:60, together with a pharmaceutically acceptable carrier.

27 ~~32.~~ A method for the treatment of asthma and other inflammatory respiratory disorders which comprises administering by inhalation to a host in need of such treatment effective amounts of a physiologically acceptable salt of formoterol or a solvate thereof, and budesonide wherein the molar ratio of the formoterol component to the budesonide component is in the range from 1:1 to 1:60.

32 cont.

10 ~~33.~~ The medicament of claim 9 ~~30~~ wherein the active ingredients are in dry powder form.

11 ~~34.~~ The medicament of claim 9 ~~30~~ or 10 ~~33~~ wherein the formoterol is in the form of the fumarate dihydrate.

13 ~~35~~. The pharmaceutical composition of claim 12 ~~31~~ wherein the formoterol is in the form of the fumarate dihydrate.

28 ~~36~~. The method according to claim 27 ~~32~~, wherein the effective amount of the physiologically acceptable salt of formoterol or solvate thereof is 6-100 μg per day, and the effective amount of budesonide is 50-4800 μg per day.

29 ~~37~~. The method according to claim 28 ~~36~~ wherein the effective amount of the physiologically acceptable salt of formoterol or solvate thereof is 6-48 μg per day, and the effective amount of budesonide is 100-1600 μg per day.

30 ~~38~~. The method according to any one of claims 27 ~~32~~, 28 ~~36~~ and 37 wherein the administration is performed from a dry powder inhaler.

31 ~~39~~. The method according to claim 30 ~~38~~ wherein the inhaler is a Turbuhaler™.

32 ~~40~~. The method according to any one of claims 27 ~~32~~, 28 ~~36~~ and 29 ~~37~~ wherein the administration is performed from a metered dose inhaler.

32 cont

33 ~~41~~. The method according to any one of claims 27 ~~32~~, 28 ~~36~~ and 29 ~~37~~ wherein the formoterol is in the form of the fumarate dihydrate.

14 ~~42~~. A pharmaceutical composition according to claim 12 ~~31~~ wherein the pharmaceutically acceptable carrier is lactose.